LPL Antibody - #BF0636
製品: | LPL Antibody |
カタログ: | BF0636 |
タンパク質の説明: | Mouse monoclonal antibody to LPL |
アプリケーション: | WB ELISA |
反応性: | Human |
分子量: | 53.1kDa; 53kD(Calculated). |
ユニプロット: | P06858 |
RRID: | AB_2833701 |
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
引用形式: Affinity Biosciences Cat# BF0636, RRID:AB_2833701.
折りたたみ/展開
EC 3.1.1; EC 3.1.1.34; HDLCQ11; LIPD; LIPL_HUMAN; Lipoprotein lipase; LPL; LPL protein; MGC137861;
免疫原
Purified recombinant fragment of human LPL expressed in E. Coli.
Detected in blood plasma (PubMed:2340307, PubMed:11893776, PubMed:12641539). Detected in milk (at protein level) (PubMed:2340307).
- P06858 LIPL_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MESKALLVLTLAVWLQSLTASRGGVAAADQRRDFIDIESKFALRTPEDTAEDTCHLIPGVAESVATCHFNHSSKTFMVIHGWTVTGMYESWVPKLVAALYKREPDSNVIVVDWLSRAQEHYPVSAGYTKLVGQDVARFINWMEEEFNYPLDNVHLLGYSLGAHAAGIAGSLTNKKVNRITGLDPAGPNFEYAEAPSRLSPDDADFVDVLHTFTRGSPGRSIGIQKPVGHVDIYPNGGTFQPGCNIGEAIRVIAERGLGDVDQLVKCSHERSIHLFIDSLLNEENPSKAYRCSSKEAFEKGLCLSCRKNRCNNLGYEINKVRAKRSSKMYLKTRSQMPYKVFHYQVKIHFSGTESETHTNQAFEISLYGTVAESENIPFTLPEVSTNKTYSFLIYTEVDIGELLMLKLKWKSDSYFSWSDWWSSPGFAIQKIRVKAGETQKKVIFCSREKVSHLQKGKAPAVFVKCHDKSLNKKSG
PTMs - P06858 基板として
Site | PTM Type | Enzyme | Source |
---|---|---|---|
S17 | Phosphorylation | Uniprot | |
T19 | Phosphorylation | Uniprot | |
S21 | Phosphorylation | Uniprot | |
K40 | Ubiquitination | Uniprot | |
N70 | N-Glycosylation | Uniprot | |
T75 | Phosphorylation | Uniprot | |
S196 | Phosphorylation | Uniprot | |
K265 | Ubiquitination | Uniprot | |
K299 | Ubiquitination | Uniprot | |
S304 | Phosphorylation | Uniprot | |
Y329 | Phosphorylation | Uniprot | |
Y343 | Phosphorylation | Uniprot | |
N386 | N-Glycosylation | Uniprot | |
K408 | Acetylation | Uniprot | |
T438 | Phosphorylation | Uniprot |
研究背景
Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage. Mediates margination of triglyceride-rich lipoprotein particles in capillaries. Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans.
Tyrosine nitration after lipopolysaccharide (LPS) challenge down-regulates the lipase activity.
Cell membrane>Peripheral membrane protein>Extracellular side. Secreted. Secreted>Extracellular space>Extracellular matrix.
Note: Newly synthesized LPL binds to cell surface heparan proteoglycans and is then released by heparanase. Subsequently, it becomes attached to heparan proteoglycan on endothelial cells (PubMed:27811232). Locates to the plasma membrane of microvilli of hepatocytes with triglyceride-rich lipoproteins (TRL). Some of the bound LPL is then internalized and located inside non-coated endocytic vesicles (By similarity).
Detected in blood plasma. Detected in milk (at protein level).
Homodimer (Probable). Interacts with GPIHBP1 with 1:1 stoichiometry. Interacts with APOC2; the interaction activates LPL activity in the presence of lipids (By similarity). Interaction with heparan sulfate proteoglycans is required to protect LPL against loss of activity. Associates with lipoprotein particles in blood plasma. Interacts with LMF1 and SEL1L; interaction with SEL1L is required to prevent aggregation of newly synthesized LPL in the endoplasmic reticulum (ER), and for normal export of LPL from the ER to the extracellular space. Interacts with SORL1; SORL1 acts as a sorting receptor, promoting LPL localization to endosomes and later to lysosomes, leading to degradation of newly synthesized LPL.
Belongs to the AB hydrolase superfamily. Lipase family.
研究領域
· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.
· Metabolism > Lipid metabolism > Glycerolipid metabolism.
· Organismal Systems > Endocrine system > PPAR signaling pathway.
· Organismal Systems > Digestive system > Cholesterol metabolism.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.